Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Expected to Grow at 18.5% CAGR Through 2029: Industry Forecast

 Unlock 30% Off Global Market Reports Using Code ONLINE30 — Stay Informed on Trade Policies, Market Growth, and Key Disruptors

 

 What Is the Expected Market Growth Rate for the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
 The ribonucleic acid (RNA)-based oncolytic therapy market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to increasing cancer prevalence, rising investment in healthcare infrastructure, growing awareness of targeted therapies, expansion of clinical trial programs, and increasing government funding for oncology research.
 
 The ribonucleic acid (RNA)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to increasing adoption of RNA-based therapies, growing focus on immuno-oncology, rising biotechnology collaborations, expansion of advanced manufacturing facilities, and increasing access to precision medicine. Major trends in the forecast period include technological advancements, developments in viral vector design, investment in research and development, innovation in delivery systems, and development of combination therapy approaches.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28321&type=smp
 
 Which Major Growth Drivers Will Influence the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market by 2029?
 The growing adoption of personalized medicine is expected to propel the growth of the RNA-based oncolytic therapy market going forward. Personalized medicine refers to medical treatments tailored to individual genetic profiles, improving efficacy and reducing adverse effects. The adoption of personalized medicine is increasing as more healthcare providers and institutions recognize the potential to enhance patient outcomes through targeted therapies and precision diagnostics. RNA-based oncolytic therapy plays a crucial role in cancer care by aligning with the growing adoption of personalized medicine to deliver targeted and patient-specific treatment approaches. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the RNA-based oncolytic therapy market.
 
 How Is the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segmented?
 The ribonucleic acid (RN)-based oncolytic therapy market covered in this report is segmented as
 
 1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
 2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations
 3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
 4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
 
 Subsegment:
 1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
 2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
 3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
 4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents
 
 What Are the Major Trends Impacting the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
 Major companies are operating in the ribonucleic acid (RNA)-based oncolytic therapy market, focusing on developing technological advancements such as synthetic messenger RNA (mRNA) technology to enhance tumor-targeting efficiency, improve immune activation, and achieve more precise and durable cancer treatment outcomes. Synthetic messenger RNA (mRNA) technology is a biotechnology approach that designs and delivers lab-made mRNA sequences to direct cells to produce specific therapeutic proteins for disease treatment, including cancer. For instance, in June 2024, CSPC Pharmaceutical Group Limited, a China-based pharmaceutical company, received regulatory approval in China to initiate clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This development represents a major advancement in the country’s messenger RNA therapeutics landscape. SYS6020 employs mRNA-lipid nanoparticle technology to selectively target and eliminate myeloma cancer cells with minimal adverse effects, while also demonstrating potential applications in the treatment of certain autoimmune diseases.
 
 Which Organizations Are Key Contributors to the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
 Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.
 
 Get the full ribonucleic acid (rna)-based oncolytic therapy market report here:
 https://www.thebusinessresearchcompany.com/report/ribonucleic-acid-rna-based-oncolytic-therapy-global-market-report
 
 What Are the Regional Market Share Projections for the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?
 North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA)-based oncolytic therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company